Synaffix
Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology out-licensing business model. Synaffix was fully acquired by Lonza in June 2023. Aimed at enabling innovative medicines for patients in areas of high unmet medical need, Synaffix has forged a growing number of collaborations with top tier biotech and pharma companies by enabling best-in-class therapeutic candidates for their pipelines. Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecific.
– GlycoConnect™ enables best-in-class therapeutic efficacy and tolerability
– HydraSpace® further differentiates efficacy and tolerability versus other site-specific ADC approaches
– toxSYN® linker-payloads provide multiple options to maximize efficacy in light of tumor biology
– Proprietary DAR1 technology
